Please login to the form below

risankizumab

This page shows the latest risankizumab news and features for those working in and with pharma, biotech and healthcare.

Lilly reports positive data from its phase 3 ulcerative colitis trial

For Crohn’s, mirikizumab is in a close race with AbbVie’s IL-23 inhibitor Skyrizi (risankizumab), which recently met both primary endpoints of clinical remission and endoscopic response at week

Latest news

Skyrizi, Rinvoq help AbbVie weather Humira slowdown

news. Quick take-up of new immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) have encouraged AbbVie to predict the pair will together make around $1.7bn in sales this year, well
Cosentyx, Entresto drive topline growth for Novartis in Q4

However, in head-to-head trials with both AbbVie’s Humira (adalimumab) and Skyrizi (risankizumab), Cosentyx failed to show superiority – a potential sign of trouble ahead as the psoriasis/biologic market
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

Skyrizi. The head-to-head study pitted IL-23 antagonist Skyrizi (risankizumab) against Novartis’ blockbuster IL-17 inhibitor Cosentyx (secukinumab) – which has sales currently running at around $1bn a quarter – and
AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis

The pharma company has been pushing Rinvoq (upadacitinib) into the RA market, while its Boehringer Ingelheim-partnered drug Skyrizi (risankizumab) has been making headway in psoriasis.
J&J splashes $750m on anti-inflammatory drug bermekimab

secukinumab) and AbbVie’s Skyrizi (risankizumab).

More from news
Approximately 3 fully matching, plus 27 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma companies to watch

AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

Sales are projected at $1.93bn for 2013. Skyrizi (risankizumab) treats psoriasis.
Drug launches to watch in 2019

It announced the filing of upadacitinib in the US and Europe on 20 December, with the filing of risankizumab expected early this year. ... The analysis showed that 56% of patients on risankizumab were symptom-free after a year’s treatment, compared to

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Content Editor - Biotechnology: Salary TBC

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Account Management: Competitive Salary Offered

PMHub

Add my company

Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

How a design mindset can lead to better medical outcomes: By adopting a design philosophy, healthcare companies can develop communications that allow healthcare professionals (HCPs) to better meet the needs of their patients. Imaginatively designed content combined with patient insights...
How does the government plan to reshape the NHS?: Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care...
Want to give perfect client service? Tough luck, you’re human: In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...